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ABSTRACT  
 The ability of tumor cells to metastasize is increasingly viewed as an 
interaction between the primary tumor and host tissues.  Deletion of the p19/Arf 
or p53 tumor suppressor genes accelerates malignant progression and 
metastatic spread of DMBA/TPA-induced squamous cell carcinomas, providing a 
model system to address mechanisms of metastasis.  Here we show that benign 
pre-metastatic papillomas from wild type mice trigger lymphangiogenesis within 
draining lymph nodes, while there is no growth of primary tumor lymphatic 
vessels.  Lymph node lymphangiogenesis is greatly accelerated in papilloma-
bearing p19/Arf- or p53-deficient mice, which coincides with the greater 
propensity of these tumors to progress to carcinomas and to metastasize. The 
extent of accumulation of B cells within the tumor-draining lymph nodes of wild 
type mice predicted the level of lymph node lymphangiogenesis and metastatic 
potential.  Arf or p53 deficiency strongly accelerated lymph node immune cell 
accumulation, in a manner that was associated with the extent of lymph node 
lymphatic sinus growth. This immune cell accumulation and lymph node 
lymphangiogenesis phenotype identifies host anti-tumor responses that could 
drive metastatic spread of cancers via the lymphatics. 
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INTRODUCTION   
 Murine cancer models have been useful to define the critical genes and 
multi-step pathways involved in generation of cancers.  However, most mouse 
cancer models rarely develop metastasis to secondary organs, so that the 
genetics and biology of this process has been less studied.  Murine or human 
cancers can metastasize via the vascular or lymphatic systems (Cao, 2005).  
Blood vessel growth (angiogenesis) in primary tumors could provide a direct 
route for tumor dissemination by intravasation of tumor cells into the abnormal 
vasculature.  Lymphatic vessel growth (lymphangiogenesis) in or around tumors 
is similarly thought to provide a direct means to transport tumor cells to draining 
lymph nodes (LNs), and subsequently into the pulmonary circulation.  For this 
reason, tumor cell detection in tumor-draining or sentinel LNs is used clinically to 
diagnose metastasis of human cancers including melanoma, breast, and colon 
cancer (Nathanson, 2003).  As metastasis is the major cause of death in cancer 
patients, it is critical to develop mouse cancer models that reliably metastasize, 
to identify events required for dissemination by either pathway. 
Evidence that the lymphatic system actively contributes to tumor 
metastasis has come from studies of lymphatic endothelial growth factors.  
Vascular endothelial growth factor (VEGF-A) stimulates lymphangiogenesis by 
activating VEGFR-2 expressed on lymphatic endothelium, however VEGF-A 
additionally promotes VEGFR-2-dependent blood vessel growth (Nagy et al., 
2002).  While VEGF-A overexpression stimulates lymphangiogenesis and 
metastasis (Hirakawa et al., 2005), and VEGFR-2 blockade inhibits metastasis 
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(Roberts et al., 2006), these manipulations additionally alter angiogenesis and 
tumor size.  The VEGF-C and VEGF-D growth factors selectively influence 
lymphatic endothelial proliferation and migration, without affecting vascular 
endothelium, by activating VEGFR-3 expressed on lymphatic endothelium 
(Baldwin et al., 2004).  Tumor VEGF-C or VEGF-D expression is associated with 
human cancers having poor prognosis (reviewed by (Stacker et al., 2002)), 
suggesting that lymphangiogenesis promotes metastasis.   Moreover, ectopic 
VEGF-C or VEGF-D drive tumor lymphangiogenesis and LN metastasis in 
murine cancers (Mandriota et al., 2001; Skobe et al., 2001b; Stacker et al., 
2001), while inhibition of VEGFR-3 signalling blocks metastasis (He et al., 2002; 
Krishnan et al., 2003; Shimizu et al., 2004).  However, LN metastasis can occur 
without tumor lymphangiogenesis (Achen and Stacker, 2006; Wong and Hynes, 
2006), indicating that other alterations contribute to tumor dissemination via 
lymphatics. 
 While tumor cells can metastasize to draining LNs, an active contribution 
of LNs to tumor dissemination was not considered until recently.  We discovered 
in an Eμ−c-myc lymphoma model that Myc-expressing B cell accumulation within 
LNs is associated with growth of LN lymphatic sinuses (Ruddell et al., 2003). 
Lymphangiogenesis was also identified in LNs draining melanomas after 
subcutaneous implantation, but prior to metastasis to draining LNs (Harrell et al., 
2007).  LN lymphatic sinus growth had functional consequences, as lymph flow 
through draining LNs increased 20- to 30-fold.  These observations led us to 
propose that LN lymphangiogenesis and increased lymph flow actively drive 
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tumor cells to draining LNs (Ruddell et al., 2003).  In support of this idea, ectopic 
VEGF-A or VEGF-C overexpression in murine skin tumors promoted tumor 
lymphatic vessel growth, LN lymphangiogenesis, and increased metastasis 
(Hirakawa et al., 2007; Hirakawa et al., 2005).  Our previous studies identified B 
cells as the natural mediators of lymphangiogenesis in melanoma-draining LNs, 
as B cell-deficient mice did not support LN lymphatic sinus growth (Harrell et al., 
2007).  Taken together, these findings suggest that B cell–induced LN 
lymphangiogenesis promotes metastasis to draining LNs. 
 We used a murine multi-stage model of squamous cell carcinoma to 
assess the contributions of lymphangiogenesis and angiogenesis within the 
primary tumor or draining LN to metastasis.  Two-stage treatment of mice with 
DMBA carcinogen, followed by multiple TPA treatments, produces benign 
squamous cell papillomas within 3 months, which feature thickened and folded 
epidermis (Kemp, 2005).  The epithelial cells invariably feature DMBA-induced 
mutation and constitutive activation of the Ha-ras oncogene (Kemp et al., 1993; 
Quintanilla et al., 1986).  DMBA-induced papillomas can sometimes convert to 
carcinomas invading through the underlying dermis, and occasionally 
metastasizing to draining LNs and lungs.  Mutations or LOH of the p19/Arf or p53 
tumor suppressors arise during carcinoma conversion, and Arf- or p53-deficient 
mice show increased carcinomas, indicating that Arf or p53 loss is rate limiting 
for malignant progression (Burns et al., 1991; Kelly-Spratt et al., 2004; Kemp et 
al., 1993).  These tumor suppressors also block metastasis, as DMBA-TPA-
treated mice deficient for Arf or p53 show increased LN and lung metastases 
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(Kelly-Spratt et al., 2004; Kemp et al., 1993), providing a genetic model to 
evaluate mechanisms of carcinoma metastasis.   
Two complementary approaches were used to identify vessel alterations 
associated with squamous cell carcinoma metastasis.  Firstly, lymphatic and 
blood vessels of papillomas, carcinomas, or tumor-draining LNs were compared 
to normal skin or LNs, to identify alterations promoting carcinoma dissemination 
in wild type mice.  Secondly, vessels were compared between wild type, Arf +/-, 
and p53 +/- mice, to identify alterations that could explain the increased 
susceptibility of Arf- and p53-deficient mice to metastasis.  We found that LN 
lymphangiogenesis is the major vessel alteration associated with metastatic 
potential.  Moreover, B cell accumulation predicted the extent of LN 
lymphangiogenesis, suggesting that tumor-induced B cell accumulation promotes 
LN lymphatic sinus growth and metastasis. 
 
RESULTS  
 
Angiogenesis in carcinomas of wild type and Arf +/- mice. 
 Squamous cell carcinomas spread to draining LNs before they are 
detected in lungs (Kelly-Spratt et al., 2004), suggesting that they metastasize via 
the lymphatics.  Immunohistochemical staining assessed whether lymphatic 
vessels increase in primary tumors, as a mechanism to drive metastasis.  LYVE-
1 and 10.1.1 lymphatic endothelium-specific antibodies identified lymphatic 
vessels of variable size and density in normal dermis (Figure 1A).  Benign 
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papillomas showed sparse lymphatic vessels in thickened dermis (Figure 1C), as 
did  carcinomas, which consist of undifferentiated keratinocytes (Figure 1E).  
FIGURE 1 
 MECA-32 immunostaining of blood vessels (Leppink et al., 1989) tested 
whether angiogenesis is involved in tumor progression.  Blood vessels were 
confined to the dermis in normal skin (arrowhead, Figure 1B) or papillomas 
(Figure 1D).  Carcinomas contained abundant and enlarged blood vessels, 
typical of angiogenic tumors (Figure 1F).  These findings agree with previous 
measurements of 4-fold increased blood vessel density in DMBA/TPA-induced 
carcinomas, while intra- or peri-tumoral lymphatic vessels showed little growth 
(Hirakawa et al., 2003).  Thus angiogenesis rather than lymphangiogenesis is the 
major vessel alteration in carcinomas from wild type mice. 
 Lymphatic and blood vessels were characterized in tumors from Arf +/- 
mice, to determine whether vessel growth could accelerate metastasis in this 
genotype.  Lymphatic vessels were sparse in papillomas (Figure 1G) and 
carcinomas (Figure 1I) from Arf +/- mice.  Carcinomas from Arf-deficient mice 
showed angiogenesis (Figure 1J) similar to that in wild type mice (Figure 1F).  
Thus accelerated metastasis in Arf +/- mice is not due to enhanced tumor 
lymphatic or blood vessel growth, relative to wild type tumors. 
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Lymph node lymphangiogenesis is an early response to pre-malignant 
tumor growth 
We previously identified LN rather than tumor lymphangiogenesis as the 
major vessel alteration associated with metastatic melanoma growth (Harrell et 
al., 2007).  The DMBA/TPA tumor model was used to ask whether LN 
lymphangiogenesis arises before carcinoma conversion, or upon metastasis to 
LNs.  First, draining inguinal LNs of mice bearing pre-metastatic papillomas were 
compared to those from untreated controls.  Control wild type LNs showed 
normal lymphatic sinuses restricted to the cortex and septum between paired 
LNs (Figure 2A).  By contrast, LNs from papilloma-bearing mice showed 
enlarged lymphatic sinuses throughout the LN (Figure 2E).  Enlarged lymphatic 
sinuses are directly attributed to papilloma formation rather than TPA treatment, 
as TPA treatment alone did not affect lymphatic sinuses (Figure 2C). 
FIGURE 2 
Comparison of lymphatic sinus area in serial LN section samples 
demonstrated a 2.5-fold increase in papilloma-draining LNs relative to untreated 
control LNs, and no significant increase in LNs from TPA-treated mice (Figure 
3A).  Lymphatic sinus growth involves proliferation, as 10.1.1-positive lymphatic 
endothelium within papilloma-draining LNs often immunostained positively for the 
mitotic marker phosphohistone H3 (data not shown}.  Thus pre-metastatic 
papillomas stimulate lymphangiogenesis in draining LNs, while the papilloma 
itself does not undergo lymphatic vessel growth.  
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MECA-32 immunostaining was used to test whether blood vessels of 
tumor-draining LNs also respond to primary tumors.  Capillaries and high 
endothelial venules were abundant in LNs from untreated control (Figure 2B), 
TPA-only (Figure 2D), or DMBA/TPA-treated papilloma-bearing mice (Figure 2F). 
Blood vessel area (Figure 3B) or density measurements (data not shown) 
confirmed that tumors do not increase LN blood vessels.  Thus, papillomas act 
over a distance to stimulate LN lymphangiogenesis, without affecting LN blood 
vessels. 
FIGURE 3 
Arf or p53 deficiency accelerates lymph node lymphangiogenesis. 
 Arf- or p53-deficient mice show increased conversion of papillomas to 
carcinomas, and more rapid metastasis (Kelly-Spratt et al., 2004).  We first 
examined LNs from papilloma-bearing Arf +/- mice, to determine whether 
accelerated metastasis involves alterations in draining LNs prior to malignant 
conversion.  LNs from papilloma-bearing Arf +/- mice showed greatly increased 
lymphatic sinuses (Figure 2I) relative to LNs from age-matched papilloma-
bearing wild type mice (Figure 2E).  This was confirmed by quantifying lymphatic 
sinus area, which identified significantly enhanced lymphangiogenesis in LNs 
from Arf-deficient versus wild type papilloma-bearing mice (Figure 3A).  By 
contrast, Arf deficiency did not affect blood vessels in papilloma-draining LNs 
(Figure 2J), confirmed by quantification (Figure 3B).  Arf deficiency therefore  
strongly and selectively promotes lymphatic sinus growth at the pre-malignant 
papilloma stage, prior to metastasis.  
 10
 Papillomas grow more rapidly in Arf-deficient mice (Kelly-Spratt et al., 
2004), which could potentially explain enhancement of LN lymphangiogenesis in 
Arf +/- mice.  This hypothesis was tested by examining papilloma-draining LNs of 
p53 +/- mice, which also show rapid carcinoma conversion and metastasis, 
however they grow more slowly than wild type papillomas.  LNs from papilloma-
bearing p53 +/- mice showed extensive lymphangiogenesis (Figure 2K), similar 
to that in Arf +/- mice (Figure 2I).  Lymphatic sinus area quantitation confirmed 
that p53 or Arf deficiency significantly increased LN lymphangiogenesis (Figure 
3A). This is not due to intrinsic differences in LN lymphatics, as control LNs from 
wild type (Figure 2A), Arf- (Figure 2G), or p53-deficient mice (Supplementary 
Figure 1A) all showed few lymphatic sinuses.  Arf or p53 tumor suppressor 
deficiency thus specifically accelerates tumor-induced LN lymphangiogenesis in 
a manner which is associated with an increased probability of carcinoma 
conversion and metastasis, that is independent of tumor growth rate.  
 
Lymph node lymphangiogenesis in wild type carcinoma-bearing mice. 
LN metastases occasionally arise in carcinoma-bearing wild type mice.  
Wild type mice bearing carcinomas were examined to determine whether LN 
lymphangiogenesis is associated with this stage of tumor progression.  These 
LNs consistently showed greatly increased lymphatic sinuses (Figure 4A) relative 
to LNs from papilloma-bearing mice (Figure 2E). Quantification confirmed that 
lymphatic sinus area increases 4-fold relative to untreated controls (Figure 3A).  
This increase is much larger than that in papilloma-draining LNs (Figure 3A), 
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indicating that lymphatic sinus growth continues during tumor progression in wild 
type mice.  By contrast, carcinoma-draining LN blood vessels (Figure 4B) are 
similar to those of papilloma-draining LNs (Figure 2F), and this was confirmed by 
measuring blood vessel area (Figure 3B).   These findings demonstrate that 
carcinoma conversion provides a strong and specific lymphatic growth stimulus 
within draining LNs of wild type mice. 
FIGURE 4 
Lymphatic sinus remodeling in carcinoma-draining LNs from Arf- and p53-
deficient mice 
 Thus far we identified enhanced lymphangiogenesis in papilloma-bearing 
Arf +/- mice relative to wild type mice.  We investigated whether accelerated 
carcinoma conversion and metastasis in Arf +/- mice further enhances LN 
lymphangiogenesis.  Surprisingly, the LN lymphatic sinuses of carcinoma-bearing  
Arf +/- mice were greatly reduced (Figure 4C) relative to LNs from Arf +/- mice 
bearing only papillomas (Figure 2I).  Quantification confirmed that lymphatic 
sinus area in Arf +/- LNs was not significantly increased relative to normal LNs 
(Figure 3A).   
Arf deletion accelerates carcinoma conversion and metastasis, so that 
tumor cells are detected in most LNs from carcinoma-bearing Arf +/- mice (Kelly-
Spratt et al., 2004).  Tumors were identified by their distinct morphology, and by 
immunostaining for podoplanin (Schacht et al., 2005), or keratin (Kelly-Spratt et 
al., 2004).  The LN shown (Figure 4C) is typical of LNs that do not yet contain 
tumors, indicating that lymphatic sinus loss in carcinoma-bearing Arf +/- mice 
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begins before metastases are detected.  Similar loss of LN lymphatic sinuses 
was identified in carcinoma-bearing p53 +/- mice (Supplementary Figure 1C). 
We next analyzed LNs from Arf +/- mice containing podoplanin-positive 
metastases (“T”, Figure 4H).  Sparse lymphatic sinuses were found adjacent to 
and within metastases by 10.1.1 (Figure 4E), or LYVE-1 immunostaining (Figure 
4G), as were MECA-32-positive blood vessels (Figure 4F).  These remaining LN 
lymphatic sinuses could potentially mediate further tumor dissemination via the 
lymphatics. 
Carcinoma metastases grow aggressively in Arf +/- mice, so that tumors 
can entirely replace LNs (Kelly-Spratt et al., 2004).  These LNs contained 
minimal lymphatic sinuses (arrow, Figure 4I), while blood vessels greatly 
increased (Figure 4J), indicating that tumor growth destroys lymphatic sinuses, 
while it concurrently stimulates angiogenesis.  This same phenotype was 
observed in primary tumors, where lymphatic vessels were sparse (Figure 1I), 
while blood vessels were abundant (Figure 1J).  Taken together, these findings 
suggest that carcinoma cells are selectively toxic for lymphatic endothelium.  LN 
metastasis often is detected in Arf-deficient mice at the time of carcinoma 
conversion (Kelly-Spratt et al., 2004), suggesting that the arrival of small 
numbers of tumor cells in draining LNs could trigger lymphatic sinus degradation, 
before LN metastases grow large enough to be detected.  
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Arf or p53 deficiency enhances macrophage accumulation in tumor-
draining LNs 
 Our finding that LN lymphangiogenesis arises at the papilloma stage, prior 
to metastasis, suggests that tumors produce a long-range signal driving LN 
lymphatic sinus growth. Migratory immune cells could traffic from primary tumors 
or from the blood stream into draining LNs in response to tumors.  Alternatively, 
tumor-derived factors could travel via the lymph to activate draining LNs.  One 
immune cell type that could contribute is macrophages, which can secrete 
VEGF-A, VEGF-C, and VEGF-D to drive lymphatic and blood vessel growth 
(Schoppmann et al., 2002; Skobe et al., 2001a).   
We performed immunohistochemical staining of tumors and draining LNs 
using the F4/80 antibody, to determine whether macrophages could contribute to 
vessel growth during tumor progression.  F4/80-positive macrophages were 
identified within papillomas (Figure 5B), but not in normal skin (Figure 5A).  
Carcinomas showed extensive macrophage infiltration (Figure 5C).  Papillomas 
and carcinomas from Arf +/- mice showed similar macrophage infiltration (data 
not shown), indicating that tumor macrophages do not mediate increased LN 
lymphangiogenesis in Arf-deficient mice. 
FIGURE 5 
 Macrophages could potentially promote LN lymphangiogenesis by 
accumulating within tumor-draining LNs.  F4/80-positive macrophages were 
restricted to normal LN capsules (arrow, Figure 5D), however they were 
distributed throughout papilloma-draining LNs from wild type mice (Figure 5E).  
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LNs from papilloma-bearing Arf +/- and p53 +/- mice (Figure 5F and G, 
respectively) showed increased macrophage accumulation relative to papilloma-
bearing wild type mice (Figure 5E).  Macrophage accumulation further increased 
in LNs from carcinoma-bearing Arf +/- (Figure 5I), p53 +/- (Supplementary Figure 
1F), and wild type mice (Figure 5H).   This macrophage accumulation was tumor-
induced, as untreated LNs from wild type, p53- and Arf-deficient mice all showed 
few macrophages (Figure 5D, Supplementary Figure 1E, and data not shown). 
Macrophage accumulation could contribute to tumor-draining LN 
lymphangiogenesis in wild type mice, and to its enhancement in tumor-bearing 
Arf- and p53-deficient mice.  However, maximal LN macrophage infiltration in Arf 
+/- or p53 +/- carcinoma-bearing mice is associated with loss of lymphatic 
sinuses (Figures 4C and Supplementary Figure 1C), so that macrophages do not 
support LN lymphangiogenesis during carcinogenesis. 
  
Arf or p53 deficiency enhance B cell accumulation in tumor-draining lymph 
nodes  
 We previously found that lymphangiogenesis in melanoma-draining LNs is 
mediated by LN B cell accumulation (Harrell et al., 2007).  We tested whether B 
cell accumulation also mediates DMBA/TPA tumor-induced LN alterations.  
B220-positive B cells were absent from wild type (data not shown) or Arf +/- 
papillomas (Figure 6A).  B cells were restricted to the LN cortex of untreated 
(Figure 6B) or TPA-treated wild type mice (data not shown). However, LNs from 
papilloma-bearing mice contained B cell follicles (arrows, Figure 6C), and 
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individual B cells throughout the cortex and medulla.  Irregularly shaped follicles 
and individual lymphocytes were abundant throughout carcinoma-draining LNs 
(Figure 6D), demonstrating that B cells accumulate in tumor-draining LNs of wild 
type mice during tumor progression.  
FIGURE 6 
B lymphocyte distribution was distinct in tumor-draining LNs from Arf +/- 
and p53 +/- mice.  Untreated Arf +/- (Figure 6G) and p53 +/- LNS 
(Supplementary Figure 1G) showed B cells normally restricted to the cortex.  
However, papilloma-drainng LNs from Arf +/- (Figure 6E) and p53 +/- mice 
(Figure 6F) were uniformly filled with B lymphocytes, in contrast to the discrete B 
cell follicles identified in LNs from papilloma-bearing wild type mice (Figure 6C).  
B cell localization changed again in LNs from carcinoma-bearing Arf +/- mice 
(Figure 6H) and p53 +/- mice (Supplementary Figure 1H), with B cells forming 
irregular follicles.  B cells were excluded from LN regions containing metastases 
(“T”, Figure 6I).  These findings indicate that B cell behavior is highly regulated 
during tumor progression.  Moreover, Arf and p53 can modulate host B cell 
response to tumor growth.  Overall, the conditions yielding maximal B cell 
accumulation correspond to those featuring the most extensive LN 
lymphangiogenesis, i.e. wild type carcinomas and Arf +/- or p53 +/- papillomas 
(Table 1), supporting the idea that B cells promote LN lymphangiogenesis during 
DMBA/TPA tumor progression. 
TABLE 1 
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Inverse correlation of VEGF-A or VEGF-C levels with LN 
lymphangiogenesis. 
VEGF-A and VEGF-C are the major growth factors implicated in tumor-
associated lymphangiogenesis (reviewed by (Cao, 2005)).  We tested whether 
enhanced LN lymphangiogenesis in papilloma-bearing Arf- or p53-deficient mice 
is associated with increased production of these factors by tumors or by 
accumulation in draining LNs.  ELISA assay revealed similar high levels of 
VEGF-A in wild type, Arf +/-, and p53 +/- papillomas (Figure 7A).  Surprisingly, 
VEGF-A levels actually decreased in in papilloma-draining LNs from wild type or 
Arf +/- mice, relative to untreated control LNs (Figure 7B).  VEGF-C expression 
was similar in LNs from wild type or Arf +/- papilloma-draining LNs, by 
immunoblotting (data not shown). VEGF-A and VEGF-C levels thus do not 
predict LN lymphangiogenesis, indicating that other factors regulate LN lymphatic 
sinus growth in wild type mice, and enhanced lymphangiogenesis in Arf- and 
p53-deficient mice.  
FIGURE 7 
DISCUSSION  
 The events driving successful dissemination of tumors via the lymphatics 
are of great interest for development of diagnostic and therapeutic strategies.  
We identified LN lymphangiogenesis as the major vessel alteration that precedes 
and predicts metastatic potential of squamous cell carcinomas.  Lymphatic sinus 
growth reaches its maximum in carcinoma-draining LNs of wild type mice (Table 
1), when tumors can begin to metastasize to draining LNs.  LN 
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lymphangiogenesis is maximal in Arf- or p53-deficient mice bearing papillomas, 
which readily convert to invasive carcinomas.  These findings indicate that LN 
lymphangiogenesis is a host response to pre-malignant tumors, which occurs 
prior to overt metastasis.  We previously reported that LN lymphangiogenesis in 
pre-metastatic melanomas and lymphomas is associated with greatly increased 
lymph flow, which could actively drive tumor metastasis to draining LNs (Harrell 
et al., 2007; Ruddell et al., 2003).  The extensive LN lymphangiogenesis in 
DMBA/TPA tumor-bearing mice also likely increases lymph flow to promote 
metastasis.  Increased lymph flow may be sufficient to drive carcinoma 
metastasis, or additional changes could be required for successful lymphatic 
dissemination.  Interestingly, primary tumors show minimal lymphatic vessel 
growth, indicating that tumor lymphangiogenesis does not contribute to 
metastasis in this model. 
 LN lymphangiogenesis is associated with unusual accumulation of 
macrophages and B cells within tumor-draining LNs.  Macrophages are normally 
restricted to the LN capsule, however they accumulate throughout tumor-draining 
LNs.  Macrophages can stimulate lymphangiogenesis (Kerjaschki, 2005), so that 
they could promote LN lymphatic sinus growth.  However, extensive macrophage 
accumulation within Arf +/- or p53 +/- carcinoma-draining LNs does not support 
lymphangiogenesis, so that macrophage abundance does not predict 
lymphangiogenesis (Table 1).  In contrast, B cells are restricted to tumor-draining 
LNs, where their abundance faithfully predicts the extent of LN 
lymphangiogenesis observed at each stage in wild type or tumor suppressor-
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deficient mice (Table 1), suggesting that B cells regulate LN lymphangiogenesis 
in this model.  In support of this idea, LN B cell accumulation is required for 
melanoma-induced LN lymphangiogenesis (Harrell et al., 2007), and for LN 
lymphangiogenesis in response to acute inflammation (Angeli et al., 2006).  
Taken together, these studies identify a critical role of B cells to stimulate LN 
lymphangiogenesis. 
 B cell accumulation in tumor-draining LNs could represent an immune 
response to tumor growth, as B cell follicles appeared in LNs of papilloma-
bearing wild type mice.  However, B cells uniformly filled the LNs of Arf or p53-
deficient mice bearing papillomas, without forming discrete follicles.  Melanoma-
draining LNs also uniformly filled with B cells (Harrell et al., 2007) and in this 
case there is no humoral immune response to tumor antigens (Brown et al., 
2001; Skelton et al., 2001).  Whether or not LN B cell accumulation is associated 
with an immune response, the program of B cell accumulation is very different in 
papilloma-bearing Arf- and p53-deficient versus wild type mice.  Further studies 
are required to understand the significance of changes in B cell localization within 
LNs.  Tumor-induced macrophage accumulation also likely reflects some innate 
immune response to tumor-derived signals within primary tumors and draining 
LNs. 
Our studies identified new shared functions of the Arf and p53 tumor 
suppressors in regulation of B cell and macrophage behavior, to inhibit LN 
lymphangiogenesis and metastasis.  This could be due to tumor suppressor 
deficiency within the tumor cells themselves, or within other host cell types.  Arf 
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or p53 deficiency is generated within tumor cells during carcinoma conversion 
(Kelly-Spratt et al., 2004; Kemp, 2005), so that tumor suppressor-deficient tumor 
cells mediate LN immune cell accumulation and lymphangiogenesis in 
carcinoma-bearing wild type mice.  This indicates that the accelerated LN 
immune cell accumulation and lymphangiogenesis in papilloma-bearing Arf +/- 
and p53 +/- mice is likely also due to tumor suppressor deficiency in the tumor 
cells themselves, rather than other cell types.  Arf and p53 are commonly 
mutated in human cancers, where they could also promote LN 
lymphangiogenesis and metastasis.  Our findings linking tumor suppressor 
deficiency, immune cell accumulation, and LN lymphangiogenesis with 
metastasis identify a new pathway regulating tumor dissemination via the 
lymphatics.  
The identification of factors mediating LN lymphangiogenesis is of great 
interest for development of therapeutic interventions.  Most studies thus far have 
investigated VEGF-A or VEGF-C contributions to primary tumor 
lymphangiogenesis and metastasis (Cao, 2005).  However, we found that VEGF-
A and VEGF-C abundance actually is the same or decreased in tumors or 
draining LNs from tumor suppressor-deficient mice relative to wild type mice.  
These findings do not support the simple hypothesis that tumor-derived VEGF-A 
or VEGF-C drains to LNs to induce lymphangiogenesis, or that immune cells 
accumulating within LNs produce VEGF-A or VEGF-C locally to induce 
lymphangiogenesis.  Instead, an as yet unidentified signal could regulate LN-
restricted lymphangiogenesis, which is likely to involve the accumulation of B 
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cells within tumor-draining LNs.  However, VEGF family members could still 
influence LN lymphangiogenesis in a manner not reflected by tissue 
concentration, as their bioavailability is regulated by proteolysis (Houck et al., 
1992; Joukov et al., 1997).  B cell accumulation within LNs could provide these  
proteases, or instead B cells could stimulate lymphatic sinus growth by producing 
distinct lymphatic endothelial growth factors such as FGF-2 or PDGF-BB (Cao, 
2005). 
 Our studies identified immune cell accumulation and LN 
lymphangiogenesis as the major alterations associated with metastatic potential.  
Similar alterations could be involved in human cancer metastasis.  Tumor-
reactive lymphadenopathy is common in sentinel LNs from human cancer 
patients (Ioachim and Ratech, 2002), involving LN enlargement, lymphocyte 
accumulation, and/or sinus histiocytosis (lymphatic sinus macrophage 
expansion), which resemble the tumor-draining LN alterations we identified in 
mice.  Increased lymphatic vessels have been detected in LNs draining human 
melanoma (Dadras et al., 2005), and breast cancer (Van den Eynden et al., 
2006), supporting the idea that LN lymphangiogenesis occurs in human cancers.  
Further studies should provide insight to the contribution of LN immune cell 
infiltration and lymphangiogenesis to tumor dissemination and metastasis of 
human as well as animal cancers. 
 
MATERIALS AND METHODS 
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Tumor Induction  
The shaved back skin of wild type, p19/Arf +/- (Kamijo et al., 1997)) or p53 
+/- mice (Donehower et al., 1992) were  treated with DMBA, followed by twice 
weekly applications of TPA for 15 weeks, as previously described (Kelly-Spratt et 
al., 2004).  Mice were generally sacrificed 32 weeks after DMBA treatment.  
Animal experiments were approved by the FHCRC Animal Care and Use 
Committee.    
 
Immunostaining Analysis 
Frozen tissues were serially cryosectioned to sample throughout tumors or 
LNs, and immunostained with MECA-32 (Developmental Studies Hybridoma 
Bank, University of Iowa), 10.1.1 (Farr et al., 1993), 8.1.1 podoplanin 
(Developmental Studies Hybridoma Bank, University of Iowa (Farr et al., 1993; 
Schacht et al., 2003)), LYVE-1 (Upstate, Temecula, NY), phosphohistone H3 
(Ajiro et al., 1996), F4/80 (eBioscience, San Diego, CA), or FITC-labelled B220 
(Caltag, Carlsbad, CA) antibodies, as previously described (Harrell et al., 2007).  
Immunohistochemical staining was detected with purple Vector VIP, followed by 
Methyl Green counterstaining (Vector Laboratories, Burlingame, CA).  Sections 
were also directly immunostained with FITC-labelled-B220 antibodies, after 
blocking with CD16/CD32 Fc receptor antibody (Fc Block, BD Biosciences, San 
Jose, CA).  Carcinoma cells were detected in serial sections sampling through 
tumor-draining LNs, by their larger cytoplasm and by pan-keratin (Novagen, 
Nottingham, UK) or podoplanin immunostaining (Schacht et al., 2005).  
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Lymphatic vessel area, blood vessel area, or blood vessel density in 3 sections 
sampled from at least 5 LNs were quantified in 100x magnification microscope 
images using NIH ImageJ software (National Institutes of Health, Bethesda, MD).  
 
VEGF-A ELISA  
 Frozen tumors or lymph nodes were homogenized in phosphate-buffered 
saline, lysed by two freeze-thaw cycles, centrifuged, and VEGF-A was measured 
by ELISA (R&D Systems, Minneapolis, MN).  
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1. Angiogenesis in carcinomas from wild type and Arf +/- mice.    
 Immunohistochemical staining used LYVE-1 lymphatic endothelial 
antibody (left panels) and MECA-32 vascular endothelial antibody (right panels) 
with purple staining secondary antibody detection, and methyl green 
counterstaining.  Untreated wild type skin (A and B), wild type papilloma (C and 
D), wild type carcinoma (E and F), Arf +/- papilloma (G and H), and Arf +/- 
carcinoma (I and J) samples are shown.  Lymphatic vessels (arrows) are 
occasionally observed in the dermis of normal skin, papillomas, and carcinomas 
from wild type or Arf +/- mice.  Blood vessel size and density (arrowheads) 
increases modestly in papillomas, and extensively in carcinomas from wild type 
or Arf +/- mice. Scale bar 100 μm. 
 
Figure 2.  Lymphangiogenesis in papilloma-draining LNs.  
 Inguinal LN sections from untreated wild type mice (A and B), TPA-treated 
wild type mice (C and D), papilloma-bearing wild type mice (E and F), TPA-
treated Arf +/- mice (G and H), papilloma-bearing Arf +/- mice (I and J), or 
papilloma-bearing p53 +/- mice (K and L) were immunostained with 10.1.1 
lymphatic endothelial antibody (left panels) or with MECA-32 vascular endothelial 
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antibody (right panels).  Control LNs show lymphatic sinuses (A) in the cortex 
(“C”) but not in the medulla (“M”), and in the septum between the paired inguinal 
LNs (arrow).  Small blood vessels (arrowhead) and high endothelial venules 
(arrow) are found throughout control LNs (B).  LNs from papilloma-bearing mice 
show increased and abnormal lymphatic sinuses compared to LNs from control 
or TPA only-treated wild type mice, while blood vessels do not increase.  
Papilloma-draining LNs from Arf +/- and p53 +/- mice show much more extensive 
lymphangiogenesis than LNs from wild type mice. Scale bar 100 μm. 
 
Figure 3.  Lymphatic sinus area increases in papilloma- and carcinoma-
draining lymph nodes.   
 Quantification of lymphatic sinus area (A) shows that sinuses are 
significantly increased (p < 0.0001) in LNs draining papillomas in wild type, Arf 
+/-, and p53 +/- mice, and in LNs draining carcinomas in wild type mice, relative 
to untreated controls (WT), while TPA treatment alone had no significant effect.  
Lymphatic sinuses were significantly increased further in LNs from Arf +/- or p53 
+/- papilloma-bearing mice relative to LNs from wild type papilloma-bearing mice 
(p < 0.01).   In contrast, blood vessel area (B) is not significantly different in any 
condition, by two-tailed Students t test.  Lymph node sections were sampled at 
least 3 times through 5 sectioned LNs in each condition.  Standard errors are 
shown. 
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Figure 4.  Dynamic changes in lymphatic sinuses of carcinoma-draining 
lymph nodes.   
 Lymph node sections were immunostained with 10.1.1, LYVE-1, or 
podoplanin lymphatic endothelial antibodies, or with the MECA-32 vascular 
endothelial antibody, as indicated.  Carcinoma-draining LNs from wild type mice 
(A) show much more extensive lymphatic sinuses (arrow) than those of Arf +/- 
mice (C), while blood vessels are similar in carcinoma-draining LNs from wild 
type (B) and Arf +/- (D) mice.  These LNs do not contain detectible metastases.  
Carcinoma-draining LNs from Arf +/- mice that contain metastatic tumors (“T”, to 
left of dashed line) are shown in panels E to H.  Lymphatic sinuses positive for 
10.1.1 (E), LYVE-1 (G) or podoplanin (H) are observed adjacent to tumors and 
also within the metastasis (arrow, G).  Blood vessels are found within and 
adjacent to LN regions containing metastases (F).  Metastatic carcinoma cells 
sometimes replace the entire draining LN in Arf +/- mice, and these LNs show 
greatly reduced lymphatic sinuses (arrow, I), while they undergo extensive blood 
vessel growth (J).  Scale bar 100 μm.  
 
Figure 5.  Macrophage accumulation in tumors and tumor-draining lymph 
nodes 
 Macrophages identified by immunohistochemical staining with F4/80 
antibody are detected in papillomas (arrow, B), and are major constituents of 
carcinomas (C), while they are not found in untreated skin (A) from control wild 
type mice.  Macrophages are found in the capsule (arrow) but not in the cortex 
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(“C”) or medulla (“M”) of LNs from untreated mice (D).  Macrophages appear 
throughout LNs draining papillomas of wild type mice (E), and show increased 
accumulation in LNs from Arf +/- (F) or p53 +/- (G) papilloma-bearing mice.  
Carcinoma-draining LNs from wild type (H) mice show extensive macrophage 
accumulation, which is further increased in carcinoma-draining LNs from Arf +/- 
mice (I).  Scale bar 100 μm. 
 
Figure 6.  B cell accumulation in tumor-draining LNs predicts LN 
lymphangiogenesis. 
 B cells were immunostained with FITC-labelled B220 antibody in all 
panels, and nuclei were counterstained with DAPI in panels A and I.  A).  
Papillomas from Arf +/- mice do not contain B220-positive B cells.  B).  B cells 
are confined to the cortex (“C”), and are rarely found in the medulla (“M”) of 
untreated wild type mice.  C).  B cell follicles (arrows) and individual B cells are 
detected in papilloma-draining LNs from wild type mice.  D).  B cell follicles grow 
and spread in carcinoma-draining LNs from wild type mice.  E).  B cells 
completely fill papilloma-draining LNs in Arf +/- mice.  F).  B cells completely fill 
papilloma-draining LNs in p53 +/- mice.  G).  Untreated Arf +/- LNs show normal 
pattern of cortical B cells.  H). Carcinoma-draining LNs of Arf +/- mice show 
irregular B cell follicles (arrows).  I).   LNs containing metastases from Arf +/- 
mice show exclusion of B cells from the tumor region (“T”), to the right of the 
dashed line.  Scale bar 100 μm. 
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Figure 7.  VEGF-A levels in papillomas or draining lymph nodes do not 
predict lymphangiogenesis. 
 A).  VEGF-A abundance was measured in papillomas from wild type, Arf 
+/-, or p53 +/- mice by ELISA assay.  B).  VEGF-A abundance in control wild type 
LNs and in wild type or Arf +/- papilloma-draining LNs.  VEGF-A levels 
significantly decreased in Arf +/- papilloma-draining LNs relative to wild type LNs, 
by two-tailed Student’s t test (p < 0.02).  Standard errors are shown. 
 
Supplementary Figure 1 
p53 deficiency has the same effect on tumor-draining lymph nodes as  
Arf deficiency. 
 Purple immunostaining lymphatic sinuses and blood vessels in p53-
deficient control (A, B) and carcinoma-draining lymph nodes (C, D).  F4/80 
macrophages (E, F) and FITC-B220 fluorescent B cells (G, H) in control and 
carcinoma-draining p53 +/- lymph nodes.   
 
